Priority Review for Amicus' migalastat

By Sandi Wong | Feb 12, 2018 | 10:06 PM GMT

FDA accepted and granted Priority Review to an NDA from Amicus Therapeutics Inc. (NASDAQ:FOLD) for migalastat (AT1001) to treat Fabry's

Read the full 204 word article

How to gain access

Continue reading with a
two-week free trial.